M&A Deal Summary

Cybin Acquires Adelia Therapeutics

On December 7, 2020, Cybin acquired life science company Adelia Therapeutics for 16M USD

Acquisition Highlights
  • This is Cybin’s 1st transaction in the Life Science sector.
  • This is Cybin’s largest (disclosed) transaction.
  • This is Cybin’s 1st transaction in the United States.
  • This is Cybin’s 1st transaction in Massachusetts.

M&A Deal Summary
Date 2020-12-07
Target Adelia Therapeutics
Sector Life Science
Buyer(s) Cybin
Deal Type Add-on Acquisition
Deal Value 16M USD

Target

Adelia Therapeutics

Boston, Massachusetts, United States
Adelia Therapeutics, Inc. is a biopharmaceutical company addressing unmet mental health needs through the development of proprietary psychedelic therapeutics with improved dosing efficacy and therapeutic indices. Adelia Therapeutics is based in Boston, Massachusetts.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Cybin

Toronto, Ontario, Canada
Category Company
Sector Life Science
DESCRIPTION

Cybin, Inc. is a life sciences company advancing psychedelic pharmaceutical treatments for various psychiatric and neurological conditions. Cybin is developing technologies and delivery systems, aiming to improve bioavailability, to potentially achieve the desired medicinal effects of psychedelics at low dosage levels. Cybin is based in Toronto, Ontario.

DEAL STATS #
Overall 1 of 2
Sector (Life Science) 1 of 2
Type (Add-on Acquisition) 1 of 2
State (Massachusetts) 1 of 1
Country (United States) 1 of 1
Year (2020) 1 of 1
Size (of disclosed) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2023-08-28 Small Pharma

London, United Kingdom

Small Pharma is a biotechnology company progressing a pipeline of short-duration psychedelic-assisted therapies for the treatment of mental health conditions. The company has a portfolio of clinical-stage DMT-based assets, SPL026 and SPL028. Small Pharma is focused on developing short-duration tryptamine-based therapeutics that are scalable, commercially differentiated, and conveniently dosed, with the goal of addressing key unmet needs in the treatment of depression. Its clinical-stage program, SPL026, a first-generation DMT molecule, has shown proof-of-concept for the potential treatment of MDD. In a Phase 2a study, IV SPL026 demonstrated a rapid and durable antidepressant effect, as well as a favorable safety and tolerability profile. Small Pharma is based in London.

Buy -
Mergr

Product

Company

Legal